Vivaglobin market growth forecast through 2035 driven by PI treatment demand
The Business Research Company says the Vivaglobin market is expanding on rising primary immunodeficiency diagnoses, broader use of subcutaneous immunoglobulin therapy, and higher R&D investment. North America led the market in 2025, while Asia-Pacific is projected to grow fastest through 2035.
Why it matters: - Vivaglobin is used to help patients with primary immunodeficiency maintain antibody levels and reduce infection risk. - Market growth could increase access to self-administered immune replacement therapy, especially for patients using home-based care. - The forecast points to wider demand for rare disease treatments as the global population ages and immune disorders are diagnosed more often.
What happened: - The Business Research Company published its Vivaglobin Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Vivaglobin market is growing as diagnosis and treatment options for immune system disorders improve. - The report also says awareness and acceptance of subcutaneous immunoglobulin therapies are rising alongside healthcare infrastructure expansion. - The report includes a free sample download at More information. - The full report is available at the full report.
The details: - Vivaglobin is a subcutaneous immunoglobulin therapy primarily prescribed for primary immunodeficiency, a group of disorders that weaken the immune system’s ability to fight infections. - The therapy provides a continuous supply of antibodies through subcutaneous administration. - The report says historic growth came from better diagnosis rates for primary immunodeficiency disorders, wider clinical use of SCIg therapies, growth of specialty pharmacy networks, access to plasma-derived treatments, and greater physician awareness of immune conditions. - The report says future growth should be supported by rising demand for self-administered immunoglobulin therapies, advances in personalized immunotherapy, more investment in rare disease treatments, a larger elderly population with immune challenges, and better plasma fractionation technologies. - Forecast-period trends include stronger adoption of subcutaneous immunoglobulin, preference for home-based administration, focus on long-term immune replacement, patient-centric dosing, and greater attention to safety and tolerability. - The report says increasing primary immunodeficiency cases are a major market driver. - The report cites improved diagnostic tools, better genetic testing, higher awareness, and more accurate identification of previously undiagnosed patients as reasons for the rise in diagnosed cases. - Thermo Fisher estimated in August 2023 that about 6 million people worldwide have primary immunodeficiency, including about 5,000 people in the UK. - Rising pharmaceutical R&D spending is another growth driver. - The UK Office for National Statistics reported in April 2025 that government R&D spending rose 8.2% year on year, from £16.1 billion in 2022 to £17.4 billion in 2023. - The growing geriatric population is also expected to lift demand for Vivaglobin. - The US Administration for Community Living said 17.3% of the US population was age 65 or older in 2022, and that share is projected to reach 22% by 2040. - In 2025, North America held the largest share of the Vivaglobin market. - The report says Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East, and Africa.
Between the lines: - The market story is less about a single drug and more about the broader shift toward chronic, at-home immune support for patients with rare immune disorders. - The emphasis on safety, tolerability, and patient-centric dosing suggests competition is likely to center on convenience and long-term adherence, not just efficacy. - The report’s regional split points to mature demand in North America and faster upside where diagnosis and treatment access are still improving.
What's next: - The report expects continued growth through 2035 as more patients are diagnosed and more therapy moves into home settings. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated technology and trend analysis. - The company provided contact details for further inquiries, including Saumya Sahay at marketing@tbrc.info.
The bottom line: - Vivaglobin is positioned to benefit from rising PI diagnosis rates, aging populations, and a broader shift toward home-based immunoglobulin therapy.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
World Politics Report
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.